ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Co Diagnostics Inc

Co Diagnostics Inc (CODX)

0.4781
-0.0169
(-3.41%)
Closed March 03 3:00PM
0.4781
0.00
( 0.00% )
Pre Market: 6:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.4781
Bid
0.455
Ask
0.53
Volume
-
0.00 Day's Range 0.00
0.4749 52 Week Range 2.2299
Market Cap
Previous Close
0.4781
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
217,905
Shares Outstanding
31,929,752
Dividend Yield
-
PE Ratio
-0.42
Earnings Per Share (EPS)
-1.14
Revenue
6.81M
Net Profit
-36.41M

About Co Diagnostics Inc

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI'... Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Salt Lake City, Utah, USA
Founded
-
Co Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker CODX. The last closing price for Co Diagnostics was US$0.48. Over the last year, Co Diagnostics shares have traded in a share price range of US$ 0.4749 to US$ 2.2299.

Co Diagnostics currently has 31,929,752 shares outstanding. The market capitalization of Co Diagnostics is US$15.27 million. Co Diagnostics has a price to earnings ratio (PE ratio) of -0.42.

CODX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1759-26.89602446480.6540.6550.47492044110.52093154CS
4-0.2569-34.95238095240.7350.770.47491879330.63796843CS
12-0.372-43.75955769910.85011.070.47492179050.76314064CS
26-0.8219-63.22307692311.31.580.47491608660.92170784CS
52-0.6619-58.06140350881.142.22990.47491664891.20624985CS
156-5.1519-91.50799289525.637.130.47492091693.25185373CS
260-13.0819-96.474188790613.5631.40.4749119389412.73895382CS

CODX - Frequently Asked Questions (FAQ)

What is the current Co Diagnostics share price?
The current share price of Co Diagnostics is US$ 0.4781
How many Co Diagnostics shares are in issue?
Co Diagnostics has 31,929,752 shares in issue
What is the market cap of Co Diagnostics?
The market capitalisation of Co Diagnostics is USD 15.27M
What is the 1 year trading range for Co Diagnostics share price?
Co Diagnostics has traded in the range of US$ 0.4749 to US$ 2.2299 during the past year
What is the PE ratio of Co Diagnostics?
The price to earnings ratio of Co Diagnostics is -0.42
What is the cash to sales ratio of Co Diagnostics?
The cash to sales ratio of Co Diagnostics is 2.25
What is the reporting currency for Co Diagnostics?
Co Diagnostics reports financial results in USD
What is the latest annual turnover for Co Diagnostics?
The latest annual turnover of Co Diagnostics is USD 6.81M
What is the latest annual profit for Co Diagnostics?
The latest annual profit of Co Diagnostics is USD -36.41M
What is the registered address of Co Diagnostics?
The registered address for Co Diagnostics is 2401 S. FOOTHILL DRIVE, SUITE D, SALT LAKE CITY, UTAH, 84109
What is the Co Diagnostics website address?
The website address for Co Diagnostics is www.codiagnostics.com
Which industry sector does Co Diagnostics operate in?
Co Diagnostics operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PTIXProtagenic Therapeutics Inc
US$ 0.4299
(55.59%)
22.9M
BTOGBit Origin Ltd
US$ 0.4319
(35.26%)
42.83M
LNKSLinkers Industries Ltd
US$ 0.85
(30.77%)
53
UOKAMDJM Ltd
US$ 0.193
(28.67%)
3.67M
GCLGCL Global Holdings Ltd
US$ 2.59
(28.22%)
554
SPGCSacks Parente Golf Inc
US$ 0.1072
(-43.58%)
11.21M
SYRESpyre Therapeutics Inc
US$ 11.00
(-38.68%)
4
EVCMEverCommerce Inc
US$ 6.20
(-36.28%)
7
OPCHOption Care Health Inc
US$ 22.01
(-35.19%)
17
EOLSEvolus Inc
US$ 9.32
(-35.01%)
8
SUNESUNation Energy Inc
US$ 0.2143
(-10.71%)
47.74M
BTOGBit Origin Ltd
US$ 0.4284
(34.17%)
42.83M
AGMHAGM Group Holdings Inc
US$ 0.12
(-9.77%)
24.72M
PTIXProtagenic Therapeutics Inc
US$ 0.427
(54.54%)
22.9M
SPGCSacks Parente Golf Inc
US$ 0.1069
(-43.74%)
11.21M

CODX Discussion

View Posts
Schrodingers Cat Schrodingers Cat 9 hours ago
Mar 3 short volumes: CODX 34%, FLGT 69%, QDEL 54%, VERU 56%.
👍️0
Schrodingers Cat Schrodingers Cat 3 days ago
Feb 28 short volumes: CODX 22%, FLGT 56%, QDEL 57%, VERU 67%.
👍️0
Schrodingers Cat Schrodingers Cat 4 days ago
Feb 27 short volumes: CODX 25%, FLGT 42%, QDEL 63%, VERU 58%.
👍️0
Schrodingers Cat Schrodingers Cat 5 days ago
Feb 26 short volumes: CODX 24%, FLGT 68%, QDEL 87%, VERU 63%.
👍️0
Schrodingers Cat Schrodingers Cat 6 days ago
Feb 25 short volumes: CODX 14%, FLGT 64%, QDEL 87%, VERU 46%.
👍️0
Schrodingers Cat Schrodingers Cat 1 week ago
Feb 24 short volumes: CODX 44%, FLGT 62%, QDEL 88%, VERU 55%
👍️0
Schrodingers Cat Schrodingers Cat 1 week ago
Feb 21 short volumes: CODX 49%, FLGT 63%, QDEL 78%, VERU 54%.
👍️0
Schrodingers Cat Schrodingers Cat 2 weeks ago
Feb 20 short volumes: CODX 24%, FLGT 55%, QDEL 75%, VERU 69%.
👍️0
Schrodingers Cat Schrodingers Cat 2 weeks ago
Feb 19 short volumes: CODX 17%, FLGT 59%, QDEL 78%, VERU 71%.
👍️0
Schrodingers Cat Schrodingers Cat 2 weeks ago
Feb 18 short volumes: CODX 43%, FLGT 52%, QDEL 64%, VERU 55%.
👍️0
Schrodingers Cat Schrodingers Cat 2 weeks ago
Feb 14 short volumes: CODX 9%, FLGT 50%, QDEL 69%, VERU 48%.
👍️0
Schrodingers Cat Schrodingers Cat 3 weeks ago
Feb 13 short volumes: CODX 10%, FLGT 41%, QDEL 56%, VERU 58%.
👍️0
Schrodingers Cat Schrodingers Cat 3 weeks ago
Feb 12 short volumes: CODX 12%, FLGT 65%, QDEL 70%, VERU 65%.
👍️0
Schrodingers Cat Schrodingers Cat 3 weeks ago
Feb 11 short volumes: CODX 10%, FLGT 68%, QDEL 84%, VERU 68%.
👍️0
Schrodingers Cat Schrodingers Cat 3 weeks ago
Feb 10 short volumes: CODX 25%, FLGT 47%, QDEL 73%, VERU 46%.
👍️0
Schrodingers Cat Schrodingers Cat 3 weeks ago
Feb 7 short volumes: CODX 15%, FLGT 72%, QDEL 74%, VERU 59%.
👍️0
Schrodingers Cat Schrodingers Cat 4 weeks ago
Feb 6 short volumes: CODX 20%, FLGT 65%, QDEL 62%, VERU 54%.
👍️0
Schrodingers Cat Schrodingers Cat 4 weeks ago
Feb 5 short volumes: CODX 16%, FLGT 50%, QDEL 73%, VERU 61%.
👍️0
Schrodingers Cat Schrodingers Cat 4 weeks ago
Feb 4 short volumes: CODX 4%, FLGT 41%, QDEL 62%, VERU 75%.
👍️0
Schrodingers Cat Schrodingers Cat 4 weeks ago
Feb 3 short volumes: CODX 51%, FLGT 62%, QDEL 59%, VERU 57%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 31 short volumes: CODX 13%, FLGT 57%, QDEL 56%, VERU 45%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 30 short volumes: CODX 5%, FLGT 46%, QDEL 31%, VERU 52%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 29 short volumes: CODX 25%, FLGT 56%, QDEL 53%, VERU 59%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 28 short volumes: CODX 18%, FLGT 33%, QDEL 64%, VERU 66%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 27 short volumes: CODX 34%, FLGT 52%, QDEL 65%, VERU 68%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 24 short volumes: CODX 19%, FLGT 48%, QDEL 43%, VERU 59%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 23 short volumes: CODX 41%, FLGT 52%, QDEL 56%, VERU 42%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 22 short volumes: CODX 12%, FLGT 33%, QDEL 49%, VERU 45%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 21 short volumes: CODX 17%, FLGT 29%, QDEL 47%, VERU 45%.
👍️0
Schrodingers Cat Schrodingers Cat 1 month ago
Jan 17 short volumes: CODX 19%, FLGT 46%, QDEL 65%, VERU 34%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 16 short volumes: CODX 35%, FLGT 50%, QDEL 59%, VERU 31%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 15 short volumes: CODX 19%, FLGT 35%, QDEL 33%, VERU 30%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 14 short volumes: CODX 21%, FLGT 43%, QDEL 36%, VERU 42%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 13 short volumes: CODX 9%, FLGT 57%, QDEL 45%, VERU 35%.
👍️0
glenn1919 glenn1919 2 months ago
CODX...............................https://stockcharts.com/h-sc/ui?s=CODX&p=W&b=5&g=0&id=p86431144783
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 10 short volumes: CODX 9%, FLGT 54%, QDEL 41%, VERU 26%.
👍️0
georgie18 georgie18 2 months ago
CODX...83...Adding here...🥳...

georgie18

Member Level
Re: georgie18 post# 4136

Monday, January 06, 2025 1:20:30 PM

Post#
4137
of 4140
CODX...$1.07...on the Breakout...🥳Off my .78 Alert...

georgie18

Member Level
Re: georgie18 post# 670539

Monday, January 06, 2025 1:15:05 PM

Post#
670570
of 670573
CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 8 short volumes: CODX 22%, FLGT 32%, QDEL 49%, VERU 47%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 7 short volumes: CODX 22%, FLGT 43%, QDEL 66%, VERU 41%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 6 short volumes: CODX 32%, FLGT 34%, QDEL 52%, VERU 42%.
👍️0
georgie18 georgie18 2 months ago
CODX...$1.07...on the Breakout...🥳Off my .78 Alert...

georgie18

Member Level
Re: georgie18 post# 670539

Monday, January 06, 2025 1:15:05 PM

Post#
670570
of 670573
CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.
👍️0
georgie18 georgie18 2 months ago
CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.
👍️0
georgie18 georgie18 2 months ago
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.
👍️0
georgie18 georgie18 2 months ago
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 3 short volumes: CODX 47%, FLGT 34%, QDEL 61%, VERU 33%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Jan 2 short volumes: CODX 30%, FLGT 34%, QDEL 61%, VERU 39%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Dec 31 short volumes: CODX 35%, FLGT 33%, QDEL 56%, VERU 52%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Dec 30 short volumes: CODX 59%, FLGT 47%, QDEL 70%, VERU 56%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Dec 27 short volumes: CODX 28%, FLGT 37%, QDEL 48%, VERU 43%.
👍️0
Schrodingers Cat Schrodingers Cat 2 months ago
Dec 26 short volumes: CODX 23%, FLGT 33%, QDEL 55%, VERU 48%.
👍️0

Your Recent History

Delayed Upgrade Clock